University of Tuebingen; Department of Psychiatry & Psychotherapy; Institute of Medical Psychology and Behavioural Neurobiology
Tübingen, Baden-Wurttemberg, 72076, Germany
Location status: Recruiting
NCT Number: NCT06222749
Oxytocin is a hypothalamic neuropeptide that is best known for its peripheral physiological effects in the female organism i.e., uterine contractions during birth. The neuropeptide furthermore affects reward processing and metabolic functions such as eating behavior and body weight. Oxytocin receptors are present in brain regions associated with the processing of rewards, e.g., ventral tegmental area (VTA), nucleus accumbens (NAcc) and nucleus stria terminalis.
Previous studies indicate that oxytocin interacts with sex hormones such as estradiol in a sex-specific manner. Despite known sex differences in oxytocin function, most studies i.e., on the metabolic effects of oxytocin in humans have so far focused on young, healthy men.
Intranasal oxytocin administration has emerged as a method to experimentally investigate central nervous effects of oxytocin in the absence of relevant side effects.
In the proposed study the investigators aim to systematically investigate the acute effect of intranasal oxytocin on reward processing in relation to circulating and synthetic sex hormones in healthy, naturally cycling women and in women taking hormonal oral contraceptive pills. The investigators will administer 24 international units (IU) of intranasal oxytocin vs. placebo and investigate neural correlates in a 3T MRI scanner including functional imaging during a reward processing task, changes in brain anatomy and connectivity. Additionally, metabolic functions, eating behavior and changes in mood and wellbeing will be assessed and blood will be drawn to assess parameters of hormonal and metabolic status.
Interested in participating?
Request Info18 year–40 year
Female
Interventional
Not applicable
Tübingen, Baden-Wurttemberg, 72076, Germany
Location status: Recruiting
This pharmaco-neuroimaging study will investigate four groups of women: (1) naturally cycling (NC) women in the follicular phase of the menstrual cycle (n = 25), (2) NC women in the luteal phase of the menstrual cycle (n = 25), (3) women taking combined oral hormonal contraceptives (OC) (n = 25), (4) women taking progestogen-only OC (n = 25).
All participants will take part in an intake session (T0) and two experimental sessions (T1 and T2) scheduled approximately four weeks apart. In the intake session (T0) the eligibility of the participants i.e., MRI compatibility, will be verified. Additionally, the participants will be asked to fill out questionnaires i.e., regarding their personality, sleep and eating behavior and perform standardized cognitive tests.
To disentangle the influence of oxytocin on reward processing and metabolism across different hormonal status in females, intranasal oxytocin (24 IU) will be administered in one experimental session and placebo in another, in a randomized and double-blind study design. The investigators will obtain sex steroids (e.g., progesterone, estrogen, testosterone) i.e., to verify the menstrual cycle phase, synthetic steroids (e.g., ethinylestradiol, levonorgestrel) and metabolic hormones (e.g., glucose, insulin, c-peptide) from blood samples in the two experimental sessions. In the baseline phase of each experimental session (T1 and T2), the investigators will assess the participants body composition with bioimpedance analysis and resting energy expenditure with indirect calorimetry. After the intranasal administration of oxytocin or placebo, a 3 Tesla (3T) functional magnetic resonance imaging (fMRI) session will follow including the Effort Allocation Task (EAT), an effort-based decision-making task, a resting-state fMRI and diffusion tensor imaging (DTI) scan. The experimental sessions will furthermore assess the participants mood, thirst and hunger throughout the experimental period and include a snack test to assess eating related behavior. Additionally, participants will be asked to fill out questionnaires assessing i.e., sleep, emotion regulation, decision making, sexual function and wellbeing.
The investigators hypothesize that, (1) the acute effect of oxytocin on reward processing in naturally cycling women is most pronounced during the follicular phase and (2) the acute effect of oxytocin on reward processing in women is dampened by the intake of oral contraceptive pills (OCs), in particular progestogen-only pills.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
Other names: Syntocinon
Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Other names: Placebo
Time frame: During neuroimaging (60 minutes) oxytocin compared to placebo condition.
Comparing brain activity (BOLD signals) in the reward circuitry (ROIs: nucleus accumbens, putamen, caudate, ventral tegmental area, amygdala, ventromedial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, insula) and cognitive control areas (ROIs: dorsolateral and ventromedial prefrontal cortex, anterior cingulate cortex, supplementary motor area) of female participants in luteal menstrual cycle phase, follicular menstrual cycle phase, with combined OC intake and progestogen-only OC intake during a reward task with oxytocin vs placebo.
Time frame: During neuroimaging (60 minutes) oxytocin compared to placebo condition.
Force exerted on grip force controller to obtain rewards and changes in behavioral parameters measured during the Effort Allocation Task after oxytocin vs. placebo administration.
Time frame: During the experimental session (approximately 4.5 hours).
Number of consumed calories (kcal) in a snack test and subjective satiety in oxytocin vs. placebo condition.
Time frame: During neuroimaging (60 minutes) oxytocin compared to placebo condition.
Functional connectivity of regions of the mesocorticolimbic circuitry (ROIs: nucleus accumbens, putamen, caudata, ventral tegmental area, amygdala, ventral medial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex) and limbic circuity (ROIs: hypothalamus, hippocampus) after oxytocin vs. placebo administration.
Time frame: During the experimental session (approximately 4.5 hours).
Cortisol concentrations assessed by blood samples after oxytocin vs. placebo administration.
Time frame: Measured in each experimental session, approximately 4 weeks apart; between-subject outcome
Changes in resting energy expenditure, measured by indirect calorimetry.
Contact information is provided by the study sponsor or research team.
Johannes Klaus, MD
CONTACT
Manfred Hallschmid, Professor
CONTACT
International Research Training Group 2804
Other
The Role of Oxytocin in Reward Processing Across the Menstrual Cycle and With Oral Contraceptive Use
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07699224
Abnormal Uterine Bleeding (AUB), Dysmenorrhea
Madrid, Spain
View Trial DetailsNCT07456202
Menstrual Cycle, Nausea
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07591818
Athlete, Menstrual Cycle
Cruz Quebrada, Oeiras, Portugal
View Trial DetailsNCT06771583
Depressive Disorder, Menstrual Cycle
Baltimore, Maryland, United States
View Trial Details